10-K: Viridian Therapeutics Secures $300M in Revenue Rights Deal, Advances TED Pipeline

Viridian Therapeutics, Inc. announced a significant revenue participation right sale of up to $300 million and provided updates on its advanced Thyroid Eye Disease (TED) programs, veligrotug and elegrobart, alongside its FcRn and TSHR inhibitor portfolios.

Summary

• Viridian Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for serious and rare diseases, particularly Thyroid Eye Disease (TED).
• The company reported a net loss of $342.6 million for the year ended December 31, 2025, compared to $269.9 million in 2024, with an accumulated deficit of $1,338.5 million.
• Cash, cash equivalents, and marketable securities totaled $874.7 million as of December 31, 2025.
• Viridian entered into a Purchase and Sale Agreement with DRI Healthcare Acquisitions LP (DRI) in October 2025, selling rights to certain U.S. revenue streams for up to $300 million, including $55 million upfront and up to $245 million in conditional payments.
• The DRI agreement includes tiered royalties on U.S. net sales of veligrotug, elegrobart, and related products: 7.5% up to $600 million, 0.8% between $600 million and $900 million, 0.25% between $900 million and $2 billion, and 0% above $2 billion.
• The company's lead product candidate, veligrotug (IV for TED), had its Biologics License Application (BLA) submitted to the FDA in October 2025, accepted for filing, and granted Priority Review in December 2025, with a PDUFA target action date of June 30, 2026.
• An MAA for veligrotug was also submitted to the EMA in January 2026.
• Elegrobart (SC for TED) has completed enrollment for its pivotal Phase 3 REVEAL-1 (132 patients) and REVEAL-2 (204 patients) clinical trials, exceeding target enrollments due to demand.
• Topline data for REVEAL-1 is anticipated in Q1 2026, and for REVEAL-2 in Q2 2026.
• Enrollment for elegrobart's safety study (321 patients) and auto-injector study (87 patients) was completed in October and December 2025, respectively.
• VRDN-006 (FcRn inhibitor) showed IgG reductions consistent with its class and spared albumin and LDL in Phase 1 healthy volunteer trials, with future development plans expected in 2026.
• VRDN-008 (half-life extended bispecific FcRn inhibitor) demonstrated a three-times longer half-life and deeper, more sustained IgG reduction than efgartigimod in NHP studies; IND cleared in January 2026, with healthy volunteer data expected in H2 2026.
• A TSHR inhibitor candidate for Graves disease and TED is in development, with an IND submission anticipated in Q4 2026.
• The Hercules Loan and Security Agreement was amended in October 2025, extending the maturity date to October 1, 2030, and increasing the aggregate principal amount to $300 million, with $50 million drawn to date.
• A Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. in July 2025 granted exclusive rights for veligrotug and elegrobart in Japan for an upfront payment of $70 million and potential milestones up to $315 million plus tiered royalties.
• The company maintains a strong cash position, expecting current cash, cash equivalents, marketable securities, potential near-term milestone payments, and anticipated commercial revenues to fund operations to break even if veligrotug and elegrobart are approved on anticipated timelines.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive development. The company has made significant clinical progress with its lead candidates and secured substantial non-dilutive and debt financing, significantly strengthening its financial position and de-risking its near-term operational funding, despite increasing net losses typical for a biotech at this stage.

Positives

• Secured significant non-dilutive financing of up to $300 million through a Revenue Participation Right sale with DRI Healthcare Acquisitions LP, with $55 million received upfront.
• Veligrotug's BLA was accepted for filing by the FDA and granted Priority Review, with a PDUFA target action date of June 30, 2026, indicating a potentially expedited path to market.
• Positive topline data from veligrotug's Phase 3 THRIVE and THRIVE-2 trials demonstrated highly statistically significant improvements across all measured signs and symptoms of TED, with a generally well-tolerated safety profile.
• Veligrotug showed rapid onset of treatment effect (proptosis response as early as three weeks) and durability at 52 weeks in THRIVE (70% of proptosis responders maintained response).
• THRIVE-2 is the first global Phase 3 study in chronic TED to show statistically significant and clinically meaningful diplopia responder rates and complete resolution.
• Elegrobart's Phase 3 REVEAL-1 and REVEAL-2 trials completed enrollment ahead of target due to strong patient demand, suggesting high interest in the subcutaneous formulation.
• Elegrobart demonstrated a prolonged half-life (40-50 days) in Phase 1 studies, four to five times that of veligrotug, supporting less frequent, more convenient subcutaneous dosing.
• VRDN-006 (FcRn inhibitor) showed IgG reductions consistent with its class and spared albumin and LDL in Phase 1, indicating a favorable safety profile.
• VRDN-008 (FcRn inhibitor) demonstrated a three-times longer half-life and deeper, more sustained IgG reduction than efgartigimod in NHP studies, positioning it as a potential best-in-class subcutaneous option.
• The Kissei Agreement provides $70 million upfront and potential future milestones/royalties, expanding the commercial reach of veligrotug and elegrobart into Japan.
• The Hercules Loan and Security Agreement was amended to increase the facility to $300 million and extend the maturity date to October 1, 2030, providing additional capital flexibility.
• The company's current cash, cash equivalents, and marketable securities of $874.7 million are expected to fund planned operations for at least twelve months and potentially to break even with anticipated revenues.

Negatives

• The company incurred a net loss of $342.6 million for the year ended December 31, 2025, an increase from $269.9 million in 2024, and has an accumulated deficit of $1,338.5 million.
• The additional milestone payments from the DRI Purchase and Sale Agreement (up to $245 million) are conditional on achieving specific clinical trial and regulatory approvals or commercial sales by certain dates, which are not guaranteed.
• Royalties to DRI could increase to low-double digits if elegrobart marketing approval is not received prior to a specified date.
• The company has never generated revenue from product sales and anticipates continued significant losses for the foreseeable future.
• There is a risk that the elegrobart auto-injector study may not show bioequivalence, or global health authorities may not agree with the methodologies, potentially delaying BLA submission or marketing approval.
• The company relies on single-sourced manufacturing with WuXi Biologics (Hong Kong) Limited for drug substance and drug product, which poses supply chain risks, especially given increased governmental focus on Chinese companies (e.g., BIOSECURE Act).
• Geopolitical tensions and potential trade restrictions, including those related to China, could negatively impact the company's supply chain and clinical trials.
• The company's ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership changes or future tax law changes.
• The market price of the company's common stock has historically been volatile and may continue to fluctuate significantly.

Risks

• Inability to secure additional capital when needed, forcing delays, reductions, or elimination of research and product development programs or future commercialization efforts.
• Clinical trials are costly, time-consuming, and inherently risky, with potential for failure to demonstrate safety and efficacy or significant delays.
• Regulatory approval processes are lengthy, unpredictable, and may be delayed or denied due to various factors, including disruptions at the FDA.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial viability, or result in negative consequences post-approval.
• Heavy dependence on the success of product candidates in clinical development, with no assurance of generating data sufficient for regulatory approval.
• Results of earlier nonclinical studies and clinical trials may not be predictive of future clinical trial results, and preliminary data are subject to change.
• Inability to establish commercial manufacturing, sales, and marketing capabilities or secure third-party agreements for commercialization, leading to inability to generate revenue.
• Substantial competition from larger, better-funded biotechnology and pharmaceutical companies, with competitors potentially developing or commercializing products faster or more successfully.
• Reliance on third parties (CROs, CDMOs) for nonclinical development, clinical trials, and manufacturing, with risks of non-performance, non-compliance, or supply disruptions.
• Ongoing regulatory oversight post-approval, with potential for significant liability if compliance is not maintained or if new problems arise.
• Market may not be receptive to approved product candidates, impacting profitability and future business prospects.
• Inability to obtain or maintain effective intellectual property protection (patents, trade secrets, confidentiality agreements), impairing competitive ability.
• Insufficient patent term protections for product candidates, leading to earlier competition.
• Changes in patent laws could diminish patent value and increase prosecution/enforcement costs.
• Third-party claims of intellectual property infringement, potentially preventing or delaying development and commercialization efforts.
• Dependence on intellectual property licensed from third parties, with risks of losing license rights due to non-compliance or business relationship disruptions.
• Claims challenging inventorship of patents and other intellectual property.
• Inability to protect intellectual property rights globally, especially in countries with less extensive protection.
• Product candidates regulated as biologics may face competition from biosimilar and interchangeable biological products, potentially shortening exclusivity.
• Failure to receive Fast Track, Breakthrough Therapy, or Priority Review designations, or if received, these designations may not lead to faster development or approval.
• Inability to obtain accelerated approval or failure of confirmatory trials post-accelerated approval, leading to delays or withdrawal of approval.
• Business operations and market access arrangements subject to healthcare regulatory laws, with potential for penalties for non-compliance.
• Failure to obtain or maintain adequate pricing, reimbursement, or insurance coverage for products, limiting marketability and revenue generation.
• Manufacturing complexities, including for combination products, leading to production difficulties, product loss, or supply chain interruptions.
• Reliance on Chinese manufacturers (e.g., WuXi Biologics) and potential impact from U.S. legislation (e.g., BIOSECURE Act), trade restrictions, or geopolitical tensions.
• Inability to realize potential benefits from collaborations due to insufficient resource commitment, disagreements, or termination.
• Inability to attract, retain, and motivate qualified personnel, impacting product development.
• Difficulties in managing organizational growth, leading to operational disruptions.
• Unstable market and economic conditions, inflation, interest rate increases, tariffs, trade disputes, natural disasters, public health crises, and geopolitical events adversely affecting business and financial condition.
• Covenants in the Hercules Loan and Security Agreement could restrict operations, and an event of default could force early repayment.
• Failure in information technology and storage systems, or those of third parties, leading to business disruption, data breaches, and financial impact.
• Limitations on the ability to use net operating loss carryforwards and other tax attributes to offset future taxable income or taxes.
• Changes in tax laws or regulations adversely affecting the business.
• Anti-takeover provisions in charter documents, Delaware law, and contract terms making acquisition more difficult and potentially preventing management replacement.
• Bylaws designating Delaware Court of Chancery as exclusive forum for certain disputes, potentially limiting stockholders' ability to choose a favorable judicial forum.
• Future sales of shares by existing stockholders or future equity/debt issuances causing stock price decline and dilution.
• Principal stockholders exerting significant control over matters subject to stockholder approval.
• Market price volatility of common stock due to various factors, including clinical trial outcomes, regulatory interactions, and industry perception.
• Risks related to litigation and other legal proceedings.
• Costs and demands on management from complying with public company laws and regulations.
• If equity research analysts do not publish research or publish unfavorable reports, stock price and trading volume could decline.
• Failure to maintain proper and effective internal controls, impairing accurate financial statements and investor confidence.
• Risks associated with the use of artificial intelligence (AI) and other emerging technologies, including intellectual property infringement, privacy, data protection, and regulatory compliance.

Future Outlook

The company anticipates topline data for elegrobart's REVEAL-1 trial in Q1 2026 and REVEAL-2 trial in Q2 2026. It expects healthy volunteer data for VRDN-008 in H2 2026 and plans to submit an IND for its TSHR program in Q4 2026. The company believes its existing cash, cash equivalents, marketable securities, potential near-term milestone payments, and anticipated commercial revenues from veligrotug and elegrobart sales (if approved on anticipated timelines) will be sufficient to fund planned operations to break even.

Management Comments

• Management believes elegrobart has the potential to be the best-in-class anti-IGF-1R product candidate by preserving efficacy, improving safety, and maximizing convenience for patients with subcutaneous delivery.
• Management believes that the robust and consistent clinical efficacy and safety results of veligrotug, after only five infusions, support a differentiated product profile and the potential for veligrotug to be the IV treatment-of-choice for all forms of active and chronic TED.
• Management believes a later-entrant subcutaneous therapy can convert meaningful portions of an IV market and grow the overall TED market.
• Management believes inhibiting TSHR has the potential to treat both TED and Graves disease and could complement IGF-1R inhibition in TED.

Industry Context

StockSavvy.ai notes that Viridian Therapeutics is operating in a highly competitive biopharmaceutical landscape, particularly in the Thyroid Eye Disease (TED) and FcRn inhibitor markets. The company's strategy to develop both intravenous (veligrotug) and subcutaneous (elegrobart) IGF-1R inhibitors for TED positions it to potentially capture market share from the current market leader, Amgen's Tepezza, by offering improved dosing convenience and potentially differentiated efficacy/safety profiles. The FcRn inhibitor portfolio targets a broad array of autoimmune diseases, a significant commercial opportunity, with VRDN-008 showing promising half-life extension compared to current standards like efgartigimod. The TSHR inhibitor program further diversifies the pipeline into Graves disease and TED, addressing validated disease mechanisms. The substantial non-dilutive financing and expanded debt facility reflect investor confidence in the company's pipeline progress, particularly the advanced TED programs, and provide crucial capital in a challenging funding environment for biotech.

Comparison to Industry Standards

• Veligrotug's five-dose IV regimen features fewer infusions and a shorter time per infusion compared to Tepezza (teprotumumab), the currently marketed IGF-1R inhibitor, which requires eight doses.
• Elegrobart's prolonged half-life of 40-50 days is four to five times that of veligrotug (10-12 days), positioning it for less frequent subcutaneous dosing compared to both veligrotug and Tepezza.
• VRDN-006 demonstrated comparable potency and IgG reductions to efgartigimod (Argenx's Vyvgart), the current standard of care in FcRn inhibition, in non-human primate (NHP) studies, while sparing albumin and LDL.
• VRDN-008 demonstrated three times the half-life of efgartigimod and a deeper, more sustained IgG reduction in NHP studies, with IgG levels returning to baseline 35 days after dosing compared to 14 days for efgartigimod, suggesting a potentially best-in-class subcutaneous option.
• Tepezza's 2025 net sales were approximately $1.9 billion, with estimated single-digit annual penetration of the addressable moderate to severe TED population, indicating a large untapped market that Viridian's candidates aim to penetrate.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any legal proceedings that it believes would have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• The Zenas Agreements (license agreement, letter agreements, and manufacturing development and supply agreement) with Zenas BioPharma (and its sublicensee Zai Lab) are considered related party transactions because Fairmount Funds Management LLC beneficially owns more than 5% of the company's capital stock and has a board seat on Zenas BioPharma.
• The Paragon Agreements (Research Agreement and Amended Paragon License Agreement) are considered related party transactions because Fairmount beneficially owns more than 5% of the company's and Paragon's capital stock, and has appointed the sole director on Paragon's board.

Stakeholder Impact

• **Shareholders**: Potential for dilution from future equity raises, but also potential for significant value creation if product candidates achieve regulatory approval and commercial success. The non-dilutive financing from DRI provides capital without immediate equity dilution.
• **Employees**: Increased headcount to support research, development, and commercial activities, along with competitive benefits and equity incentive plans, aims to attract and retain talent. Rule 10b5-1 trading plans adopted by executives indicate planned stock sales.
• **Customers/Patients**: Development of potential best-in-class medicines for serious and rare diseases like TED, with a focus on improved efficacy, safety, and convenience (e.g., subcutaneous elegrobart), aims to provide better treatment options.
• **Creditors**: The Hercules Loan and Security Agreement provides significant debt financing, secured by company assets (excluding IP), with covenants that could limit operational flexibility. The DRI revenue participation right is treated as a financing liability.
• **Suppliers/Partners**: Continued reliance on third-party CROs and CDMOs (e.g., WuXi Biologics) for development and manufacturing, with efforts to diversify the supply chain to mitigate risks.

Next Steps

• Report topline data for elegrobart's REVEAL-1 Phase 3 clinical trial in Q1 2026.
• Report topline data for elegrobart's REVEAL-2 Phase 3 clinical trial in Q2 2026.
• Receive FDA approval for veligrotug by the PDUFA target action date of June 30, 2026.
• Communicate future development plans for VRDN-006 in 2026.
• Generate healthy volunteer data for VRDN-008 in H2 2026.
• Submit an IND for the TSHR inhibitor program in Q4 2026.
• Continue building commercial infrastructure for anticipated launch of veligrotug, if approved.
• Prepare for commercialization of elegrobart, including auto-injector device, if approved.
• Monitor and potentially establish development and/or manufacture of product candidates at new manufacturers to strengthen supply chain robustness and mitigate reliance on single-sourced CDMOs like WuXi Biologics.

Key Dates

Recommendation

Viridian Therapeutics has made substantial progress in its clinical pipeline, particularly with veligrotug's BLA submission and Priority Review, and elegrobart's completed Phase 3 enrollment. The significant non-dilutive financing from DRI and the expanded Hercules debt facility provide a strong cash runway, mitigating immediate liquidity concerns. However, the company remains pre-revenue with increasing net losses, and future success is highly contingent on regulatory approvals and successful commercialization, which are inherently uncertain. While the clinical data is promising, the stock has likely priced in much of this positive news. A 'hold' recommendation is appropriate as investors await critical topline data for elegrobart in Q1/Q2 2026 and the FDA's decision on veligrotug by June 30, 2026, which will be key catalysts for future price movements. The risks associated with clinical development, regulatory hurdles, and intense competition in the biotech sector warrant caution, but the strong financial position and pipeline progress suggest continued potential.

Keywords

Thyroid Eye Disease, TED, Veligrotug, Elegrobart, IGF-1R, FcRn inhibitor, VRDN-006, VRDN-008, TSHR inhibitor, Biopharmaceutical, Clinical Trials, Phase 3, FDA Approval, BLA, PDUFA, Revenue Participation Right, DRI Healthcare Acquisitions, Kissei Pharmaceutical, Hercules Capital, Autoimmune Diseases, Graves Disease, Drug Development, Biologics, Orphan Drug, Breakthrough Therapy, Subcutaneous, Intravenous, WuXi Biologics, Supply Chain, Intellectual Property, Capital Raise, Net Loss, Cash Position, Biotech